Innate Pharma (IPHA) Common Equity (2017 - 2025)
Innate Pharma's (IPHA) quarterly Common Equity came in at -$25.3 million in Q4 2025, down 367.63% YoY from $9.4 million in Q4 2024, and down 533.89% on a QoQ basis from $5.8 million in Q2 2025.
Innate Pharma (IPHA) Common Equity (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Common Equity data on file, last reported at -$25.3 million in Q4 2025.
- Quarterly Common Equity fell 367.63% year-over-year to -$25.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$25.3 million (down 367.63% YoY) and the FY2025 annual result came in at -$25.3 million, down 367.63% from the prior year.
- Common Equity declined to -$25.3 million in Q4 2025, from $5.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $160.8 million in Q2 2021 to a low of -$25.3 million in Q4 2025.
- A 5-year average of $60.3 million and a median of $55.5 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity rose 1.08% — and 2025, when it plunged 367.63%.
- Tracing IPHA's Common Equity over 5 years: stood at $122.9 million in 2021, then slumped by 55.05% to $55.2 million in 2022, then increased by 1.08% to $55.8 million in 2023, then tumbled by 83.1% to $9.4 million in 2024, then slumped by 367.63% to -$25.3 million in 2025.
- The last three Common Equity figures came in at -$25.3 million (Q4 2025), $5.8 million (Q2 2025), and $9.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | Innate Pharma | 199.79 Mn | 199.79 Mn | - | -25.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -25.26 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Dec 31, 2024 | 9.44 Mn |
| Jun 30, 2024 | 31.01 Mn |
| Dec 31, 2023 | 55.84 Mn |
| Jun 30, 2023 | 63.01 Mn |
| Dec 31, 2022 | 55.25 Mn |
| Jun 30, 2022 | 124.13 Mn |
| Dec 31, 2021 | 122.91 Mn |
| Jun 30, 2021 | 160.84 Mn |
| Dec 31, 2020 | 185.97 Mn |
| Jun 30, 2020 | 207.76 Bn |
| Dec 31, 2019 | 240.66 Mn |
| Dec 31, 2018 | 190.89 Mn |
| Dec 31, 2017 | 101.21 Mn |